TERF2IP Antibody

What is TERF2IP and why is it important in telomere research?

TERF2IP is a key component of the Shelterin complex that interacts with TERF2 (Telomeric Repeat Binding Factor 2) to maintain telomere integrity and genome stability. It plays critical roles in telomere protection and DNA damage response pathways. Research has shown that the TERF2-TERF2IP interaction is essential for preventing telomeric DNA degradation and unwanted DNA repair activities at chromosome ends . TERF2IP's importance stems from its role in:

• Stabilizing telomeric structures

• Preventing inappropriate DNA repair at telomeres

• Regulating telomere length maintenance

• Contributing to chromosomal stability

• Participating in telomere-associated protein complexes

Understanding TERF2IP function is particularly important in cancer research, as dysregulation of telomere maintenance proteins, including TERF2 and its interacting proteins, has been implicated in tumorigenesis and cancer progression .

What are the most common applications for TERF2IP antibodies in research?

TERF2IP antibodies are versatile tools in telomere biology research with several key applications:

When selecting applications, researchers should consider antibody validation data for their specific experimental system, as performance can vary between applications .

How should TERF2IP antibodies be validated before experimental use?

Thorough validation is essential for obtaining reliable results with TERF2IP antibodies. A methodological approach includes:

• Specificity testing: Verify that the antibody detects only TERF2IP by:

  • Using positive controls (cells/tissues known to express TERF2IP)

  • Using negative controls (cells with TERF2IP knockdown or knockout)

  • Testing in multiple applications (e.g., WB, IHC-P, FCM) to confirm consistent detection

• Antibody characterization:

  • Determine the epitope recognized by the antibody

  • Test cross-reactivity with related proteins, particularly other Shelterin components

  • Verify species reactivity (e.g., human-specific vs. cross-reactive with murine TERF2IP)

• Technical validation:

  • Titration experiments to determine optimal antibody concentration

  • Testing various fixation and antigen retrieval methods for IHC/IF applications

  • Performing blocking experiments with recombinant TERF2IP protein

• Functional validation:

  • Confirming detection of expected protein interactions (e.g., TERF2-TERF2IP)

  • Verifying expected subcellular localization patterns

  • Comparing results with alternative antibody clones if available

This comprehensive validation ensures reproducible, reliable results across research applications.

How can TERF2IP antibodies be used to study the relationship between TERF2IP and TERF2 in cancer models?

TERF2IP antibodies provide valuable tools for investigating the complex TERF2IP-TERF2 relationship in cancer research through multiple methodological approaches:

• Co-immunoprecipitation (Co-IP) strategies:

  • Use TERF2IP antibodies to pull down protein complexes and analyze TERF2 co-precipitation

  • Perform reciprocal Co-IP with TERF2 antibodies to confirm interactions

  • Compare interaction strength across cancer and normal cell lines to identify alterations

• Proximity ligation assays (PLA):

  • Employ TERF2IP and TERF2 antibodies to visualize and quantify protein-protein interactions in situ

  • Map spatial distributions of interactions in different subcellular compartments

  • Analyze how TERF2IP-TERF2 interactions change during cancer progression

• ChIP-seq approaches:

  • Conduct parallel ChIP-seq with both TERF2IP and TERF2 antibodies

  • Identify overlapping and distinct binding sites at telomeres and elsewhere in the genome

  • Correlate binding patterns with gene expression and cancer phenotypes

Recent research has demonstrated that TERF2 is upregulated in multiple cancers, including cholangiocarcinoma, diffuse large B-cell lymphoma, pancreatic adenocarcinoma, and stomach adenocarcinoma . By utilizing TERF2IP antibodies alongside TERF2 analysis, researchers can elucidate how these interacting proteins contribute to telomere dysfunction and genomic instability in tumorigenesis.

What are the best practices for using TERF2IP antibodies in immunohistochemistry of cancer tissues?

For optimal immunohistochemical detection of TERF2IP in cancer tissues, researchers should implement the following methodological strategies:

• Sample preparation optimization:

  • Fixation timing: Limit fixation to 24 hours in 10% neutral buffered formalin

  • Section thickness: Use 4-5 μm sections for consistent staining

  • Antigen retrieval: Compare heat-induced epitope retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0) to determine optimal conditions for TERF2IP detection

• Antibody protocol refinement:

  • Titration: Test different antibody dilutions (1:100 to 1:500) to optimize signal-to-noise ratio

  • Incubation parameters: Compare overnight 4°C vs. 1-hour room temperature incubation

  • Detection systems: Evaluate polymer-based vs. avidin-biotin systems for sensitivity and specificity

• Controls and validation:

  • Positive tissue controls: Include tissues with known TERF2IP expression (e.g., testis, thymus)

  • Negative controls: Omit primary antibody and use isotype-matched controls

  • Comparison with other detection methods: Correlate IHC findings with WB or mRNA expression data

• Interpretation guidelines:

  • Scoring system: Implement H-score or Allred scoring for semiquantitative assessment

  • Subcellular localization: Document both nuclear and potential cytoplasmic staining

  • Heterogeneity analysis: Assess variation in staining patterns within tumors

These practices are particularly relevant when studying TERF2IP in cancer contexts, as research indicates altered telomere maintenance protein expression correlates with cancer progression and patient outcomes .

How can TERF2IP antibodies help elucidate the role of TERF2IP in immune cell infiltration in the tumor microenvironment?

TERF2IP antibodies can be instrumental in investigating the emerging relationship between telomere maintenance proteins and tumor immunity through several methodological approaches:

• Multiplex immunofluorescence techniques:

  • Combine TERF2IP antibodies with markers for tumor-infiltrating immune cells (CD8+ T cells, macrophages, cancer-associated fibroblasts)

  • Analyze spatial relationships between TERF2IP-expressing cells and immune cell populations

  • Quantify correlations between TERF2IP expression levels and immune cell proximity

• Flow cytometry applications:

  • Use TERF2IP antibodies in multiparameter flow panels to assess expression in different immune cell subsets

  • Correlate TERF2IP expression with immune cell activation status and exhaustion markers

  • Sort TERF2IP-high vs. TERF2IP-low immune populations for functional studies

• Single-cell analysis integration:

  • Apply TERF2IP antibodies in mass cytometry (CyTOF) or CITE-seq approaches

  • Correlate TERF2IP protein levels with transcriptomic profiles at single-cell resolution

  • Identify immune cell populations with altered TERF2IP expression in the tumor microenvironment

Recent research has revealed significant correlations between TERF2 expression and the infiltration of cancer-associated fibroblasts in multiple cancer types, including bladder cancer, cervical cancer, HPV-negative head and neck cancer, pancreatic adenocarcinoma, and stomach adenocarcinoma . Additionally, TERF2 expression has shown negative correlations with lymphocyte infiltration in glioblastoma, lower-grade glioma, and uterine carcinosarcoma . These findings suggest TERF2IP may similarly influence immune contexture, which can be investigated using appropriate antibody-based methods.

What strategies can address inconsistent TERF2IP antibody staining patterns in immunohistochemistry?

Inconsistent TERF2IP immunostaining can arise from multiple technical and biological factors. Implementing the following systematic approach can help resolve these issues:

• Fixation and processing optimization:

  • Test variable fixation times (6, 12, 24 hours) to determine impact on epitope preservation

  • Compare freshly cut vs. stored sections for signal intensity differences

  • Evaluate different deparaffinization protocols for their effect on antigen accessibility

• Antigen retrieval refinement:

  • Conduct a matrix experiment comparing:

    • Heat-induced vs. enzymatic retrieval methods

    • Different pH buffers (pH 6.0, 8.0, and 9.0)

    • Variable retrieval durations (10, 20, 30 minutes)

  • Document optimal conditions that produce consistent TERF2IP detection

• Antibody selection considerations:

  • Compare monoclonal vs. polyclonal antibodies for staining consistency

  • Test multiple antibody clones recognizing different TERF2IP epitopes

  • Evaluate lot-to-lot variation by requesting performance data from manufacturers

• Signal amplification approaches:

  • Implement tyramide signal amplification for low-abundance detection

  • Test polymer-based detection systems of varying sensitivities

  • Optimize chromogen development timing (1-10 minutes) with close monitoring

• Controls for interpretation:

  • Use cell lines with known TERF2IP expression levels as controls

  • Include gradient controls (high, medium, low expression) on each staining run

  • Document expected subcellular localization patterns in different tissue types

Research has demonstrated that telomere maintenance proteins can show variable expression and localization patterns across different cancer types and stages , highlighting the importance of optimized detection protocols.

How can researchers distinguish between specific and non-specific binding when using TERF2IP antibodies?

Distinguishing specific from non-specific TERF2IP antibody binding requires a comprehensive validation approach:

• Molecular validation techniques:

  • Genetic knockdown/knockout controls:

    • Perform siRNA or CRISPR knockout of TERF2IP

    • Compare antibody staining in wild-type vs. TERF2IP-depleted samples

    • Quantify signal reduction to determine specificity threshold

  • Blocking peptide experiments:

    • Pre-incubate antibody with excess recombinant TERF2IP protein

    • Observe elimination of specific binding while non-specific binding persists

    • Titrate blocking peptide to determine minimum concentration needed

• Technical validation approaches:

  • Multi-antibody concordance:

    • Test multiple TERF2IP antibodies recognizing different epitopes

    • Consider only consistent signals across antibodies as specific

    • Document epitope-specific variation that might reflect protein isoforms

  • Multi-method validation:

    • Correlate protein detection by WB, IF, and IHC

    • Verify consistent molecular weight in WB applications (approximately 50-55 kDa)

    • Confirm expected subcellular localization (primarily nuclear with telomeric foci)

• Signal pattern analysis:

  Signal Characteristic	Likely Specific Binding	Potential Non-specific Binding
  Subcellular localization	Nuclear, with punctate telomeric pattern	Diffuse cytoplasmic or pan-cellular
  Signal intensity correlation	Correlates with TERF2IP mRNA levels	Shows no correlation with mRNA expression
  Response to treatment	Changes with known TERF2IP regulators	Remains unchanged with TERF2IP modulators
  Molecular weight	Clean band at expected size	Multiple bands or unexpected sizes
  Tissue distribution	Matches known TERF2IP expression patterns	Ubiquitous across all tissues equally

• Cross-reactivity assessment:

  • Test antibody against recombinant proteins for related Shelterin components

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

  • Develop specificity profiles for each antibody clone based on these assessments

These approaches are particularly important when studying telomere-related proteins, as research has shown that the telomere complex contains multiple interacting proteins that share structural similarities .

How can TERF2IP antibodies be used to investigate the relationship between telomere dysfunction and cancer progression?

TERF2IP antibodies provide powerful tools for interrogating the link between telomere biology and oncogenesis through several sophisticated experimental approaches:

• Telomere dysfunction biomarker studies:

  • Employ TERF2IP antibodies alongside markers of telomere dysfunction (γ-H2AX, 53BP1)

  • Quantify co-localization of TERF2IP with these markers in pre-cancerous and cancerous tissues

  • Develop scoring systems correlating TERF2IP localization patterns with disease progression

• Telomere integrity assessment:

  • Combine immunofluorescence using TERF2IP antibodies with telomere FISH

  • Analyze TERF2IP occupancy at telomeres across cancer progression stages

  • Correlate changes in TERF2IP-telomere association with telomere length alterations

• Protein complex dynamics analysis:

  • Use proximity ligation assays with TERF2IP and TERF2 antibodies to quantify interaction frequencies

  • Track changes in Shelterin complex composition during cancer evolution

  • Correlate complex stability with genomic instability markers

• Clinical correlation studies:

  • Apply TERF2IP antibodies to tissue microarrays comprising various cancer stages

  • Develop staining algorithms that quantify expression, localization, and pattern changes

  • Correlate findings with clinical outcomes and treatment responses

Research has shown that TERF2, which directly interacts with TERF2IP, is upregulated in multiple cancer types including cholangiocarcinoma, diffuse large B-cell lymphoma, pancreatic adenocarcinoma, stomach adenocarcinoma, and thymoma . This dysregulation correlates with tumor progression in many cases. Furthermore, amplification and mutations of TERF2 have been identified as primary alterations in liver hepatocellular carcinoma . By analyzing TERF2IP in parallel with TERF2, researchers can develop a more comprehensive understanding of how telomere protection mechanisms become dysregulated during cancer development.

What methodological considerations are important when using TERF2IP antibodies to study protein-protein interactions in the Shelterin complex?

Investigating TERF2IP interactions within the Shelterin complex requires careful methodological planning:

• Optimized immunoprecipitation approaches:

  • Native vs. crosslinked IP:

    • Perform parallel IPs under native conditions and after mild crosslinking

    • Compare interaction profiles to distinguish stable vs. transient associations

    • Optimize crosslinking parameters (0.1-1% formaldehyde, 5-15 minutes) for telomeric complexes

  • Sequential IP strategies:

    • Conduct tandem immunoprecipitations (TERF2IP followed by TERF2)

    • Isolate specific subcomplexes within the larger Shelterin assembly

    • Analyze complex composition in different cellular contexts

• Advanced visualization techniques:

  • Super-resolution microscopy:

    • Apply TERF2IP antibodies in STORM or PALM imaging

    • Achieve 10-20 nm resolution of telomeric complexes

    • Analyze spatial organization of TERF2IP relative to other Shelterin components

  • Live-cell imaging adaptations:

    • Utilize cell-permeable TERF2IP antibody fragments

    • Track dynamic interactions in living cells

    • Correlate complex formation with cell cycle progression

• Functional interaction mapping:

  • Domain-specific antibodies:

    • Use antibodies recognizing specific TERF2IP domains

    • Determine which regions mediate specific protein interactions

    • Map interaction interfaces through competitive binding studies

  • Post-translational modification analysis:

    • Employ modification-specific TERF2IP antibodies (phospho, acetyl, ubiquitin)

    • Determine how modifications regulate protein interactions

    • Correlate modifications with complex assembly/disassembly

• Interaction quantification methods:

  Method	Strengths	Limitations	Best Applications
  Co-IP + Western blot	Simple, widely accessible	Semi-quantitative	Initial interaction screening
  Proximity ligation assay	In situ detection, single-molecule sensitivity	Complex optimization	Spatial interaction mapping
  FRET/BRET	Live-cell compatible, dynamic	Requires protein tagging	Real-time interaction studies
  Mass spectrometry	Unbiased, comprehensive	Sample quantity requirements	Interaction network mapping

PPI analysis has revealed that TERF2 interacts with several genes, including CTCF, DDX19A, MATR3, ZFP1, and ZFP90, which are involved in DNA binding and repair processes . These interactions highlight the complex network of telomere maintenance and suggest that TERF2IP may similarly engage in multiple protein-protein interactions that influence telomere function and genomic stability.

How can researchers integrate TERF2IP antibody-based assays with functional studies to understand telomere maintenance in cancer?

Integrating TERF2IP antibody detection with functional analyses requires a multi-dimensional approach:

• Combined genomic and proteomic profiling:

  • Correlate TERF2IP ChIP-seq data with RNA-seq and proteomics

  • Identify genes directly regulated by TERF2IP binding

  • Map the impact of TERF2IP localization on gene expression patterns

• Telomere dynamics assessment:

  • Combine TERF2IP immunostaining with telomere restriction fragment analysis

  • Correlate TERF2IP levels with telomere length maintenance

  • Track telomere erosion rates in cells with varied TERF2IP expression

• DNA damage response integration:

  • Use TERF2IP antibodies alongside DNA damage markers (γ-H2AX, 53BP1, RPA)

  • Quantify telomere dysfunction-induced foci (TIFs) in relation to TERF2IP status

  • Analyze how TERF2IP depletion affects DNA repair pathway choice at telomeres

• Cell fate determination studies:

  • Track TERF2IP expression during cellular senescence progression

  • Analyze changes in TERF2IP-telomere association during crisis

  • Determine how TERF2IP levels influence telomerase activation in cancer cells

• Therapeutic response monitoring:

  • Use TERF2IP antibodies to monitor protein dynamics during treatment

  • Correlate TERF2IP expression patterns with sensitivity to telomerase inhibitors

  • Develop combination approaches targeting both TERF2IP function and telomere maintenance

Research has demonstrated that TERF2 knockdown significantly suppresses proliferation and migration of gastric cancer cells , suggesting that targeting telomere maintenance proteins can have profound effects on cancer cell behavior. Similar functional studies with TERF2IP, integrated with antibody-based detection methods, could reveal additional therapeutic vulnerabilities in telomere maintenance pathways.

How might TERF2IP antibodies be used to explore the non-telomeric functions of TERF2IP in cellular signaling?

Recent research suggests TERF2IP may have functions beyond telomere maintenance. Antibody-based approaches to investigate these emerging roles include:

• Genome-wide mapping approaches:

  • Perform TERF2IP ChIP-seq to identify binding at non-telomeric genomic regions

  • Compare binding patterns in normal vs. cancer cells

  • Integrate with transcriptomic data to identify regulated gene networks

• Cytoplasmic function exploration:

  • Develop fractionation protocols to isolate TERF2IP from different cellular compartments

  • Use specialized fixation methods to preserve non-telomeric TERF2IP pools

  • Apply TERF2IP antibodies in proximity labeling approaches (BioID, APEX) to identify context-specific interaction partners

• Signaling pathway integration:

  • Investigate TERF2IP involvement in NF-κB signaling through co-immunoprecipitation studies

  • Analyze TERF2IP phosphorylation status using phospho-specific antibodies

  • Determine how signaling events regulate TERF2IP localization and function

• Stress response analysis:

  • Track TERF2IP localization during cellular stress using antibody-based imaging

  • Correlate changes in TERF2IP distribution with stress response pathway activation

  • Develop inducible systems to manipulate TERF2IP levels and monitor effects on stress signaling

Research has shown that telomere proteins can have diverse non-canonical functions. For example, enrichment analyses of TERF2-associated genes revealed involvement in biological processes related to "regulation of telomerase," "DNA repair," "meiosis," and "regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolism" . Similar multifunctional roles for TERF2IP can be explored using well-validated antibodies in diverse experimental contexts.

What are the best practices for using TERF2IP antibodies in combination with other telomere-related protein antibodies for multiplex analysis?

Multiplexed detection of telomere proteins requires careful consideration of antibody compatibility and detection strategies:

• Antibody selection criteria for multiplexing:

  • Host species diversity:

    • Select TERF2IP antibodies from different host species (mouse, rabbit, goat)

    • Ensure primary antibodies are compatible with available secondary detection systems

    • Consider using directly conjugated primary antibodies to eliminate cross-reactivity

  • Clone compatibility assessment:

    • Test antibody combinations on control samples before experimental use

    • Verify that signal patterns match single-antibody controls

    • Document any interference between antibodies in multiplexed settings

• Multiplexed imaging optimization:

  • Sequential detection protocols:

    • Develop stripping and re-probing protocols for TERF2IP and related antibodies

    • Validate signal loss and consistency between rounds

    • Implement image registration strategies for accurate co-localization analysis

  • Spectral unmixing approaches:

    • Utilize spectral imaging systems to separate overlapping fluorophores

    • Apply computational algorithms to resolve closely emitting fluorophores

    • Conduct careful controls to ensure accurate signal separation

• Panel design principles:

  Panel Purpose	Recommended Antibody Combinations	Technical Considerations
  Shelterin complex composition	TERF2IP + TERF2 + TERF1 + POT1	Use primary antibodies from different species
  Telomere dysfunction	TERF2IP + γ-H2AX + 53BP1 + telomere FISH	Optimize fixation to preserve antigenicity
  Telomere replication	TERF2IP + PCNA + RPA + BLM	Perform cell cycle synchronization
  Alternative lengthening of telomeres	TERF2IP + PML + RAD52 + telomere FISH	Include ALT-positive cell line controls

• Data integration frameworks:

  • Develop quantitative co-localization metrics (Pearson's, Mander's coefficients)

  • Implement machine learning algorithms to identify pattern relationships

  • Create visualization tools for multi-dimensional data representation

Research has shown that TERF2 interacts with multiple telomere-binding proteins, including TERF1, POT1, ACD, TERF2IP, and RAP1, as well as DNA damage repair proteins such as ERCC1, ERCC4, XRCC5, and ATM . Multiplexed analysis with appropriate antibodies can provide comprehensive insights into these complex interaction networks.

How can TERF2IP antibodies contribute to understanding the role of telomere biology in immune regulation within the tumor microenvironment?

Emerging evidence suggests a link between telomere maintenance proteins and immune function. TERF2IP antibodies can facilitate exploration of this frontier through:

• Spatial profiling in tumor tissues:

  • Apply multiplexed immunofluorescence with TERF2IP antibodies and immune markers

  • Analyze spatial relationships between TERF2IP-expressing cells and immune populations

  • Correlate TERF2IP expression patterns with immune exclusion or infiltration zones

• Immune cell phenotyping:

  • Assess TERF2IP expression in tumor-infiltrating immune cells using flow cytometry

  • Correlate expression with functional markers of activation, exhaustion, or senescence

  • Compare TERF2IP levels between matched peripheral and tumor-infiltrating immune populations

• Functional immunological assays:

  • Monitor TERF2IP expression during T-cell activation and exhaustion

  • Assess how TERF2IP knockdown affects immune cell function and telomere dynamics

  • Determine whether TERF2IP-targeting therapies could reinvigorate exhausted T cells

• Mechanistic studies:

  • Investigate how TERF2IP modulates NF-κB signaling in immune cells

  • Explore connections between telomere maintenance and inflammatory pathway activation

  • Determine how tumor-derived factors regulate TERF2IP expression in infiltrating immune cells

Recent research has revealed that TERF2 expression exhibits significant correlations with immune cell infiltration in various cancer types. Specifically, positive correlations were observed between TERF2 expression and cancer-associated fibroblast infiltration in bladder cancer, cervical cancer, HPV-negative head and neck cancer, pancreatic adenocarcinoma, melanoma, and stomach adenocarcinoma . Conversely, negative correlations were found between TERF2 expression and lymphocyte infiltration in glioblastoma, lower-grade glioma, and uterine carcinosarcoma . These findings suggest that telomere maintenance proteins, including TERF2IP, may influence the immune contexture of tumors and potentially represent novel immunotherapeutic targets.